Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Title: Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with
relapsing-remitting multiple sclerosis treated with interferon-beta-1b SWiss Atorvastatin and
Interferon-Beta 1b Trial In Multiple Sclerosis
Short title: "SWABIMS"
Study phase: Phase IIb study
Study design: Multi-center, randomized, rater-blinded, parallel-group-study in Switzerland
Investigational product: Atorvastatin 40mg every day (oral) plus Interferon-beta
Reference product: Interferon-beta-1b 250mg given
Indication: Relapsing-remitting multiple sclerosis (RR-MS)
Study objectives: Comparison of efficacy, safety and tolerability of combination of
Atorvastatin 40mg (per os) daily and Interferon-beta-1b e.o.d in patients with
relapsing-remitting multiple sclerosis compared to monotherapy with Interferon-beta-1b e.o.d.
Primary Endpoint: Proportion of patients with new T2 lesions after 15 months of treatment.